ABVC Biopharma Inc
NASDAQ:ABVC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Zhonghua Gas Holdings Ltd
HKEX:8246
|
HK |
|
Bounty Oil and Gas NL
ASX:BUY
|
AU |
|
Ibersol SGPS SA
LSE:0KJ7
|
PT |
|
K
|
Kuehne und Nagel International AG
XBER:KNIA
|
CH |
|
FNB Corp
NYSE:FNB
|
US |
|
Tobu Railway Co Ltd
TSE:9001
|
JP |
|
J
|
Jiangxi Firstar Panel Technology Co Ltd
SZSE:300256
|
CN |
ABVC Biopharma Inc
Total Equity
ABVC Biopharma Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ABVC Biopharma Inc
NASDAQ:ABVC
|
Total Equity
$11.1m
|
CAGR 3-Years
53%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Equity
$8.7B
|
CAGR 3-Years
33%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-11%
|
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Total Equity
$789.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-5%
|
|
|
Revolution Medicines Inc
NASDAQ:RVMD
|
Total Equity
$1.6B
|
CAGR 3-Years
34%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
United Therapeutics Corp
NASDAQ:UTHR
|
Total Equity
$7.1B
|
CAGR 3-Years
14%
|
CAGR 5-Years
16%
|
CAGR 10-Years
16%
|
|
|
Moderna Inc
NASDAQ:MRNA
|
Total Equity
$8.7B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
ABVC Biopharma Inc
Glance View
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The company is headquartered in Fremont, California and currently employs 28 full-time employees. The company went IPO on 2004-11-09. The firm develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. Its pipeline includes ABV-1501, ABV-1504, ABV-1505, ABV-1703, ABV-1601, ABV-1701 and ABV-2002. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). The company is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1501 is a combination therapy for triple negative breast cancer (TNBC). ABV-1701 is a vitreous substitute for vitrectomy. ABV-1703 is a drug for advanced inoperable or metastatic pancreatic cancer. ABV-2002 is a corneal storage media consisting of a specific polymer formulated to protect ocular tissues from osmolarity.
See Also
What is ABVC Biopharma Inc's Total Equity?
Total Equity
11.1m
USD
Based on the financial report for Dec 31, 2025, ABVC Biopharma Inc's Total Equity amounts to 11.1m USD.
What is ABVC Biopharma Inc's Total Equity growth rate?
Total Equity CAGR 5Y
26%
Over the last year, the Total Equity growth was 806%. The average annual Total Equity growth rates for ABVC Biopharma Inc have been 53% over the past three years , 26% over the past five years .
